Therapeutics to prevent allergic reactions
Areas
Health
Fields of use
Dietary Industry, Medical Industry
Current state of technology
Laboratory tests
Intellectual property
Patent pending, application number PCT/EP2018/064063
Developed by
Universitv of Ljubljana, Faculty of Pharmacy and University Clinic of Respiratory and Allergic Diseases Golnik
Reference
821-3/2017
Contact
Gabriela Droga Mazovec
Tel: +386 70 538 284
E-mail: gospodarstvo@uni-lj.si
Download PDF
- TO-Food-Alergies_EN.pdf (pdf, 332 KB)
Background
Food allergies, in particular, allergy to peanuts, are a serious public health concern that can culminate in death.There are more than 150 million people affected by allergic disease in Europe and 7 million of them suffer from food allergy. This 150 million figure is predicted to increase exponentially and it is estimated that by 2025 more than 50% of all Europeans will suffer from at least one type of allergy, with no age, social or geographical distinction.
Description of invention
Type I allergy is characterized by the production of immunoglobulin E (IgE) antibodies, against otherwise harmless antigens. Our novel peanut allergy therapy constitutes of IgE epitope-like peptides, that bind to specific IgEs and Ara h 2- specific IgEs on the surface of effector cells of patients with allergy to peanuts. Consequently, degranulation and segregation of mediators in the allergic reaction are prevented.
Main advantages
Currently, there is no definitive treatment for peanut allergy. Researchers are studying ant-IgE mAb (Omalizumab) and oral immunotherapy (desensitization), but so far this approaches have not deliver a permanent cure.